Form 990-EZ for tax year 2025

Totals

Total revenue

$74,132

Total expenses

$38,177

Contributions and grants received

$65,106

Grants paid

— not reported

Program service revenue

— not reported

Membership dues (line 3)

— not reported

Investment income (line 4)

$9,026

Gain or loss on sale of assets (line 5c)

— not reported

Gaming and fundraising events, net (line 6d)

— not reported

Gross profit on inventory sales (line 7c)

— not reported

Other revenue (line 8)

— not reported

Total assets, end of year

$382,192

Total liabilities, end of year

$450

Net assets or fund balances, end of year

$381,742

Program service expenses (Part III)

$26,724

Program services were 70.0% of total expenses calculated — Part III's total program service expenses over total expenses, both as filed.

Mission and programs · 2025

• In 2025 the NAF released a white paper titled, Clinical Trials for Neuropathy: Looking Ahead. The paper looks at how clinical trials are developing and why participation remains a critical part of discovering new therapies. We are proud to release Clinical Trials for Neuropathy: Looking Ahead, said Dominick Spatafora, NAF board president. This study helped us take a closer look at whats working, whats emerging, and how we can continue to move toward treating and preventing neuropathy. The report explores the categories that trials are currently underway: medication and biologics, regenerative or gene-related therapies, nerve-stimulation devices, and technology like virtual-reality programs or wearable monitors.The investigation also highlights innovation in the field, including precision medicine, AI tools, and new trial designs that may shorten the time it takes to understand whether a treatment works.Despite the promising aspects of neuropathic treatments, federal funding is a concern. While the biopharmaceutical industry invested more than $200 billion in research and development in 2024, recent federal budget cuts have reduced public funding for neuropathy research. This gap puts greater pressure on private investment and patient participation to keep new therapies moving forward.The study further outlines the importance of patient representation. Many communities especially older adults, women, and people from racial and ethnic minority groups remain underrepresented in neuropathy trials. The paper points out that the reasons are usually practical ones: transportation, lack of clear information, language differences, or simply not knowing a trial exists. Inclusivity is not just a scientific priority; it is a moral one. If we want treatments that work for everyone, then everyone needs a fair chance to participate. Breaking down barriers and expanding outreach will make future therapies stronger, safer, and more effective.The paper closes by encouraging more conversation between clinicians, caregivers, and patients. Community groups and advocates can also help by sharing trustworthy trial information and encouraging more people to ask questions. To access the full white paper, please visit www.neuropathyaction.org.Additionally, since its founding in 2006, the NAF has remained committed to providing neuropathy patients with essential resources to access individualized medications, IVIG, and other treatments through patient empowerment and strategic advocacy. To this end, in 2025 the NAF: Broadened our participation in national and state coalitions to maximize our impact. o To this end the NAF was part of eighteen various state and national coalitions in 2025. Expanded advocacy efforts beyond the states to national issues that impact patient access to medications, impact affordability, and research efforts. o To this end the NAF had over fifty engagements on various federal issues that impacted neuropathy awareness, funding, or access to treatments/medications. Continued our focus on state policy ensuring patients are protected from copay diversion programs, step therapy, prior authorizations, non-medical switching, and other harmful third party (health plan, government, PBM, etc.) practices. o To this end the NAF had over one hundred engagements in the states on various awareness, education, and access issues.

  Expenses $26,724

As filed on the 2025 return.

Listed in Part IV

Compensation is as filed in Part IV of the Form 990-EZ: compensation, contributions to benefit plans, expense account, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type

form_990_ez

Tax year

2025

Filed

5 June 2026

IRS schema version

2025v4.1

Source object

202631569349200608

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.